Publications by authors named "Jun Oyanagi"

Claim this Profile
A
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, Kenichi Koyama, Jun Oyanagi

BMC Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi

Cancer Immunol Immunother· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Jun Oyanagi

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter.
Mio Ikeda, Yasuhiro Koh, Jun Oyanagi, Shunsuke Teraoka, Masayuki Ishige

Anticancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Shunsuke Teraoka, Nahomi Tokudome

Clin Lung Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations.
Motohiro Izumi, Kenji Sawa, Jun Oyanagi, Ikue Noura, Mitsuru Fukui

Transl Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Jun Oyanagi

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.
Motohiro Izumi, Jun Oyanagi, Kenji Sawa, Mitsuru Fukui, Koichi Ogawa

Sci Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
Hiroaki Akamatsu, Yuichi Ozawa, Jun Oyanagi, Daichi Fujimoto, Akito Hata

Anticancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami

Cancer Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Takehito Shukuya, Jun Oyanagi, Masakuni Serizawa, Masaru Watanabe, Nobuyuki Yamamoto

Anticancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Hiroaki Akamatsu, Eriko Murakami, Jun Oyanagi, Ryota Shibaki, Takahiro Kaki

Oncologist· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto

Lung Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Motohiro Izumi

Cancer Sci· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Keita Mori, Shunsuke Teraoka

Lung Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer.
Mizuho Sakahara, Takuya Okamoto, Jun Oyanagi, Hiroshi Takano, Yasuko Natsume

Cancer Sci· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix.
Kaoru Miyazaki, Jun Oyanagi, Daisuke Hoshino, Shinsaku Togo, Hiromichi Kumagai

Sci Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin γ2 chain.
Kaoru Miyazaki, Jun Oyanagi, Atsuko Sugino, Hiroki Sato, Tomoyuki Yokose

Cancer Sci· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor.
Jun Oyanagi, Nako Kojima, Haruki Sato, Shouichi Higashi, Keiji Kikuchi

Exp Cell Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of matrix metalloproteinase-9 secretion from tumor-associated macrophage-like cells by proteolytically processed laminin-332 (laminin-5).
Go Kamoshida, Takashi Ogawa, Jun Oyanagi, Hiroki Sato, Eriko Komiya

Clin Exp Metastasis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amino-terminal fragments of laminin γ2 chain retract vascular endothelial cells and increase vascular permeability.
Hiroki Sato, Jun Oyanagi, Eriko Komiya, Takashi Ogawa, Shouichi Higashi

Cancer Sci· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial-mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel.
Jun Oyanagi, Takashi Ogawa, Hiroki Sato, Shouichi Higashi, Kaoru Miyazaki

PLoS One· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of laminin gamma2 chain monomer enhances invasive growth of human carcinoma cells in vivo.
Yoshiaki Tsubota, Takashi Ogawa, Jun Oyanagi, Yoji Nagashima, Kaoru Miyazaki

Int J Cancer· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis